BaseLaunch

BaseLaunch is a top ranked biotech accelerator

At BaseLaunch, we incubate and accelerate therapeutic ventures. BaseLaunch was named one of the top ten European Accelerators and we are always on the lookout for next-generation biotech ventures to support. We help early stage companies, researchers, scientists and entrepreneurs with growing their companies that are developing cutting-edge therapeutics. We help get them to the point where they can complete a Series A financing or similar.

Since early 2018, BaseLaunch has supported nine ventures that have, in total, raised over 200 million USD in financing. Several pharma collaborations have been initiated and one company has been sold. As of December 2019, we have added another four companies to our portfolio. Furthermore, BaseLaunch has been contributing to the development of six more ventures in the Basel Area (ABBA therapeutics, Alibion, Avicenna Oncology, Captor Therapeutics, FoRx Therapeutics, Sunregen.)

Because of our success in the first phase of the program, in 2020 the second phase has now been launched and the available funding increased to up to $500,000 per company. Partners for the second phase include: Roche, BB Pureos Bioventures, Roivant Sciences, Bridge Bioventures, CSL Behring, Johnson & Johnson.

BaseLaunch offers financing but also much more, including access to our partners, global biopharma and investors; assistance with the company and team build-out; free access to labs & related infrastructure where needed. We ensure our ventures become deeply embedded in what is arguably Europe’s strongest biotech ecosystem. The Basel Area touts academia and life science industry, a great network of talent and a hotbed for innovation.

We invite you to visit our site where you can read our success stories, learn more about the great ecosystem, and apply to participate.

BaseLaunch is managed and operated by Basel Area Business & Innovation, the innovation and investment promotion agency for the Basel Area.